Home | Emory University

Infectious Diseases Clinical Research Consortium (IDCRC)

Infectious Diseases Clinical Research Consortium

Slide 1:
Slide 2:
Slide 3:

The Infectious Diseases Clinical Research Consortium (IDCRC) and Vaccine and Treatment Evaluation Units (VTEUs) work in tandem with the National Institute of Allergy and Infectious Diseases (NIAID) as a coordinated national and global network of scientific experts working to develop and test vaccines and other therapies to combat infectious diseases.

About

The IDCRC works through a flexible, sustaining structure to advance new countermeasures and approaches to product development, implement efficient clinical study/trial designs, and support exceptional career development and mentoring of future leaders in infectious diseases clinical research. The consortium's collective experience and access to diverse populations give it the ability to evaluate new vaccines and therapies for infectious diseases.

IDCRC Active & Completed Studies

NIH begins study of COVID-19 vaccination during pregnancy and postpartum

IDCRC leads the MOMI-Vax Study

IDCRC News

COVID-19 Vaccine Appears Well-Tolerated and Effective in Developing Antibodies in Small Study of Older Adults

COVID-19 Prevention Network

The CoVPN was established by merging four existing NIAID-funded clinical trials networks: the HIV Vaccine Trials Network; the HIV Prevention Trials Network; the Infectious Diseases Clinical Research Consortium; and the AIDS Clinical Trials Group.

More about the CoVPN

COVID-19 Prevention Network launches two research studies evaluating monoclonal antibodies

IDCRC Sites Across the Nation

View World Map

News from VTEU Trials

Performance Analysis of the National Early Warning Score and Modified Early Warning Score in the Adaptive COVID-19 Treatment Trial Cohort

In the Adaptive COVID-19 Treatment Trial 1 cohort, National Early Warning Score and Modified Early Warning Score demonstrated moderate prognostic performance in patients with severe coronavirus disease 2019

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for COVID-19

Correspondence to NEJM editor

Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection

The neutralizing activity of mRNA-1273 vaccine–elicited antibodies is more RBD-targeted than that of infection-elicited antibodies

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19

The per-protocol population included 19,630 SARS-CoV-2–negative participants who received Ad26.COV2.S and 19,691 who received placebo.

IDCRC Leadership Group

IDCRC Vaccine & Treatment Evaluation Units (VTEUs)

IDCRC Concept Quick Stats

ICP Status

Approved: 25
Administratively Not Supported: 16
Revise & Resubmit: 7
Withdrawn: 7
Liaisons: 4
EWGs: 3
Not Approved: 26
EMT: 1
Other: 4

EWG Assignment

COVID: 69
Respiratory: 9
STI: 5
Malaria/Topical Diseases: 3
Enteric Infections: 2
Emerging Infections: 5

ECP

Protocol Development: 7
IDCRC Concept Study Underway: 2
Submitted to ACTIVE Mab Program per DMID: 1
Transitioned to CoVPN Trial: 1
Transitioned to ACTT 2: 1
Funded by NIAID via Other Mechanism: 1
Pending: 7
Not Approved: 0
In Process: 4
On Hold/Withdrawn: 4
Note: Protocols Transitioned to IDCRC for Protocol Implementation: 5

IDCRC Citation Statement

Please include the following citation in any publications resulting from direct or indirect IDCRC support:

"Supported by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases of the National Institutes of Health, under award number UM1AI148684. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."

Publications